Advertisement

Adjuvant Versus Neoadjuvant Androgen Deprivation With Radiotherapy for Prostate Cancer: Does Sequencing Matter?

Published:December 31, 2014DOI:https://doi.org/10.1016/j.clgc.2014.12.009

      Abstract

      Introduction/Background

      Androgen deprivation therapy (ADT) is typically provided neoadjuvantly and concurrently with radiotherapy (RT) in the management of intermediate and high-risk prostate cancer. Our objective was to compare outcomes between patients who received adjuvant ADT (ADJ), ie, immediately after the completion of RT, to those who received a neoadjuvant and concurrent regimen (NEO).

      Materials and Methods

      From 1995 to 2002, 515 patients with prostate cancer were definitively treated with RT and ADT. NEO was provided 2 to 3 months before the start of RT (n = 311). ADJ was initiated immediately after the completion of RT (n = 204). Kaplan-Meier analysis was used to calculate biochemical relapse-free survival (bRFS), distant metastasis-free survival (DMFS), and overall survival (OS). Cox proportional hazards regression was used to examine the impact of ADT timing on outcomes.

      Results

      Ten-year bRFS, DMFS, and OS rates were 61%, 80%, and 66%, respectively. Ten-year bRFS rates for ADJ versus NEO were 63% versus 60% (P = .98). Ten-year DMFS rates for ADJ versus NEO were both 80% (P = .60). Ten-year OS rates for ADJ versus NEO were 65% versus 67% (P = .98).

      Conclusion

      There was no significant difference in bRFS, DMFS, or OS between neoadjuvant versus adjuvant ADT in the setting of dose-escalated RT for localized prostate cancer. This suggests that the synergy between RT and androgen deprivation is independent of the sequencing of both modalities and that the initiation of RT does not need to be delayed for a course of neoadjuvant ADT.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Genitourinary Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pilepich M.V.
        • Winter K.
        • Lawton C.A.
        • et al.
        Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma—long-term results of phase III RTOG 85-31.
        Int J Radiat Oncol Biol Phys. 2005; 61: 1285-1290
        • Roach M.
        • Bae K.
        • Speight J.
        • et al.
        Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
        J Clin Oncol. 2008; 26: 585-591
        • Bolla M.
        • Van Tienhoven G.
        • Warde P.
        • et al.
        External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.
        Lancet Oncol. 2010; 11: 1066-1073
        • Horwitz E.M.
        • Bae K.
        • Hanks G.E.
        • et al.
        Ten-year follow-up of Radiation Therapy Oncology Group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer.
        J Clin Oncol. 2008; 26: 2497-2504
        • Bolla M.
        • de Reijke T.M.
        • Van Tienhoven G.
        • et al.
        Duration of androgen suppression in the treatment of prostate cancer.
        N Engl J Med. 2009; 360: 2516-2527
        • Lawton C.A.
        • DeSilvio M.
        • Roach M.
        • et al.
        An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions.
        Int J Radiat Oncol Biol Phys. 2007; 69: 646-655
        • Mohler J.L.
        • Armstrong A.J.
        • Bahnson R.R.
        • et al.
        Prostate cancer, version 3.2012, featured updates to the NCCN guidelines.
        J Natl Compr Canc Netw. 2012; 10: 1081-1087
        • Roach M.
        • Hanks G.
        • Thames H.
        • et al.
        Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
        Int J Radiat Oncol Biol Phys. 2006; 65: 965-974
        • Kuban D.A.
        • Tucker S.L.
        • Dong L.
        • et al.
        Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2008; 70: 67-74
        • Zietman A.L.
        • Bae K.
        • Slater J.D.
        • et al.
        Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09.
        J Clin Oncol. 2010; 28: 1106-1111
        • Peeters S.T.
        • Heemsbergen W.D.
        • Koper P.C.
        • et al.
        Dose-response in radiotherapy for localized prostate cancer: results of the dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.
        J Clin Oncol. 2006; 24: 1990-1996
        • Dubray B.M.
        • Beckendorg B.
        • Guerif S.
        Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).
        J Clin Oncol. 2011; 29: abstr 4521
        • Valicenti R.K.
        • Bae K.
        • Michalski J.
        • et al.
        Does hormone therapy reduce disease recurrence in prostate cancer patients receiving dose-escalated radiation therapy? An analysis of Radiation Therapy Oncology Group 94-06.
        Int J Radiat Oncol Biol Phys. 2011; 79: 1323-1329
        • Zelefsky M.J.
        • Yamada Y.
        • Fuks Z.
        • et al.
        Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes.
        Int J Radiat Oncol Biol Phys. 2008; 71: 1028-1033
        • Zelefsky M.J.
        • Pei X.
        • Chou J.F.
        • et al.
        Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.
        Eur Urol. 2011; 60: 1133-1139
        • Castle K.O.
        • Hoffman K.E.
        • Levy L.B.
        • et al.
        Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?.
        Int J Radiat Oncol Biol Phys. 2013; 85: 693-699
        • Zietman A.L.
        • Prince E.A.
        • Nakfoor B.M.
        • et al.
        Androgen deprivation and radiation therapy: sequencing studies using the shionogi in vivo tumor system.
        Int J Radiat Oncol Biol Phys. 1997; 38: 1067-1070
        • Kaminski J.M.
        • Hanlon A.L.
        • Joon D.L.
        • et al.
        Effect of sequencing of androgen deprivation and radiotherapy on prostate cancer growth.
        Int J Radiat Oncol Biol Phys. 2003; 57: 24-28
        • Pinthus J.H.
        • Bryskin I.
        • Trachtenberg J.
        • et al.
        Androgen induces adaptation to oxidative stress in prostate cancer: implications for treatment with radiation therapy.
        Neoplasia. 2007; 9: 68-80
        • Buttyan R.
        • Ghafar M.A.
        • Shabsigh A.
        The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression.
        Curr Opin Urol. 2000; 10: 415-420